A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma

Sponsor
Neuregen Therapeutics Co., Ltd.
Study ID
NCT07710690
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • HGG
  • High Grade Glioma
  • High Grade Glioma (III or IV)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NRG-103 — DRUG
    NRG-103

Study Details

The primary objective of this study is to determine the safe dose range of NRG-103 in patients and to recommend the dosage for subsequent treatment, while also evaluating the preliminary efficacy and tolerability of the product.

Key Dates

First listed
Jul 17, 2026
Start date
Jul 9, 2026
Status verified
Jul 2026
Primary completion
Apr 30, 2030
Completion
Apr 30, 2030

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: NRG-103

Primary Outcome Measure

AE/SAE/AESI [ Time Frame: 2 year ]

Central Contacts

Related Studies